Taysha Gene Therapies, Inc.
NASDAQTaysha Gene Therapies reports this morning with short sellers sitting on a 16.5% short interest position — one of the larger bets against a clinical-stage biotech in the gene therapy space — while every analyst covering the stock carries a buy-equivalent rating and a price target well above last night's close of $6.68. Short interest is the clearest tension here. Nearly 45.3…
Snapshot as of 16 Sept 2026
Taysha Gene Therapies reports this morning with short sellers sitting on a 16.5% short interest position — one of the larger bets against a clinical-stage biotech in the gene therapy space — while every analyst…
Taysha Gene Therapies heads into the final weeks before its August earnings date with short sellers trimming exposure and the lending pool remaining comfortably loose — a setup that contrasts with the stock's…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TSHA — free to start on ORTEX.
Sign up for free →Open TSHA on ORTEX